Phase II trial of Baker's antifol in metastatic sarcoma

Medicine and Dentistry

• Patient 100%
• Sarcoma 25%
• Toxicity 16%
• Combination Therapy 16%
• Bone Marrow Suppression 16%
• Progressive Disease 16%
• Diseases 8%
• Kidney Function 8%
• Dermatitis 8%
• Nausea and Vomiting 8%
• Stomatitis 8%
• Liver Function 8%
• Drug 8%
• Chemotherapeutic Agent 8%
• Patient History of Chemotherapy 8%
• Therapeutic Procedure 8%

Nursing and Health Professions

• Sarcoma 25%
• Triazinate 25%
• Toxicity 16%
• Combination Therapy 16%
• Bone Marrow Suppression 16%
• Diseases 8%
• Nausea and Vomiting 8%
• Drug 8%
• Dose 8%
• Death 8%
• Stomatitis 8%
• Dermatitis 8%
• Patient History of Chemotherapy 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Sarcoma 25%
• Phase II Trials 16%
• Toxicity 16%
• Bone Marrow Suppression 16%
• Diseases 8%
• Nausea and Vomiting 8%
• Dermatitis 8%
• Stomatitis 8%
• Drug 8%
• Patient History of Chemotherapy 8%
• Death 8%